LVAD Developers Look To Medicare Coverage Decision To Offset Trial Costs
This article was originally published in The Gray Sheet
Executive Summary
Launch of clinical trials for the DeBakey LVAD as destination therapy for end-stage heart failure patients is contingent on CMS issuing a national coverage decision for the expanded claim, MicroMed maintains
You may also be interested in...
CMS Bails Out Heart-Assist Device R&D, Covers Comparative LVAD Studies
CMS' decision to grant coverage to trials investigating left-ventricular assist devices has resolved much of the financial uncertainty surrounding LVAD development in recent years
CMS Bails Out Heart-Assist Device R&D, Covers Comparative LVAD Studies
CMS' decision to grant coverage to trials investigating left-ventricular assist devices has resolved much of the financial uncertainty surrounding LVAD development in recent years
Buy LVAD Now, Pay Later: WorldHeart Floats Financing Model In U.S. Market
WorldHeart will rely on a financing deal with Export Development Canada (EDC) to boost international sales of the Novacor left-ventricular assist device